UBS Group
GNOM icon

UBS Group’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

UBS Group’s Portfolio GNOM Stock Details GNOM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$546K Sell
9,603
-1,023
-10% -$48.8K ﹤0.01% 6179
2026
Q1 		$465K Sell
10,626
-3,101
-23% -$143K ﹤0.01% 6132
2025
Q4 		$624K Sell
13,727
-2,557
-16% -$113K ﹤0.01% 5951
2025
Q3 		$632K Buy
16,284
+1,084
+7% +$39.3K ﹤0.01% 5911
2025
Q2 		$513K Sell
15,200
-3,465
-19% -$110K ﹤0.01% 5984
2025
Q1 		$594K Sell
18,665
-2,396
-11% -$90.9K ﹤0.01% 5714
2024
Q4 		$818K Sell
21,061
-14
-0.1% -$588 ﹤0.01% 5466
2024
Q3 		$948K Sell
21,075
-1,925
-8% -$86.1K ﹤0.01% 4697
2024
Q2 		$960K Sell
23,000
-811
-3% -$33.9K ﹤0.01% 4458
2024
Q1 		$1.08M Sell
23,811
-654
-3% -$29.8K ﹤0.01% 4538
2023
Q4 		$1.13M Buy
24,465
+647
+3% +$26.4K ﹤0.01% 4391
2023
Q3 		$969K Sell
23,818
-1,946
-8% -$88.6K ﹤0.01% 4097
2023
Q2 		$1.25M Sell
25,764
-447
-2% -$22.4K ﹤0.01% 4017
2023
Q1 		$1.29M Sell
26,211
-1,087
-4% -$55.9K ﹤0.01% 3873
2022
Q4 		$1.38M Sell
27,298
-7,508
-22% -$387K ﹤0.01% 3763
2022
Q3 		$1.75M Sell
34,806
-6,116
-15% -$345K ﹤0.01% 3279
2022
Q2 		$2M Sell
40,922
-66,573
-62% -$3.38M ﹤0.01% 3149
2022
Q1 		$6.46M Sell
107,495
-56,913
-35% -$3.59M ﹤0.01% 2294
2021
Q4 		$13.1M Sell
164,408
-13,928
-8% -$1.17M ﹤0.01% 1915
2021
Q3 		$15.8M Buy
178,336
+4,244
+2% +$398K 0.01% 1683
2021
Q2 		$17.3M Sell
174,092
-14,565
-8% -$1.29M 0.01% 1605
2021
Q1 		$17M Buy
188,657
+54,603
+41% +$5.39M 0.01% 1552
2020
Q4 		$12.7M Buy
134,054
+28,091
+27% +$2.35M ﹤0.01% 1677
2020
Q3 		$7.62M Buy
105,963
+36,878
+53% +$2.64M ﹤0.01% 1844
2020
Q2 		$4.85M Buy
69,085
+54,029
+359% +$3.36M ﹤0.01% 2072
2020
Q1 		$750K Buy
15,056
+14,202
+1,663% +$822K ﹤0.01% 3604
2019
Q4 		$53K Buy
+854
New +$48.9K ﹤0.01% 6318

Other funds holding GNOM

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
OAM
Oppenheimer Asset Management New York $9.63B AUM 30.32% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
CFD
Creative Financial Designs Kokomo, Indiana $2.1B AUM 23.1% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
FIA
Foundations Investment Advisors Phoenix, Arizona $9.72B AUM 29.41% 1-Year Est. Return

UBS Group's GNOM Position: Q2 2026 in Review

UBS Group reduced its Global X Genomics & Biotechnology ETF (GNOM) stake by 9.6% in Q2 2026, selling an estimated $48.8K and leaving 9,603 shares worth $546K. The position accounts for ﹤0.01% of the portfolio, ranked #6179.

UBS Group first reported a position in GNOM in Q4 2019 and has held it in 27 quarters since. The position peaked at $17.3M in Q2 2021. 48 funds tracked by Wall St. Rank hold GNOM as of Q2 2026.

  • UBS Group held 9,603 shares of Global X Genomics & Biotechnology ETF worth $546K as of Q2 2026.
  • UBS Group sold 1,023 Global X Genomics & Biotechnology ETF shares in Q2 2026, an estimated $48.8K.
  • Global X Genomics & Biotechnology ETF made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6179 holding.
  • UBS Group first reported a position in Global X Genomics & Biotechnology ETF in Q4 2019 and has held it in 27 quarters since.
  • UBS Group's Global X Genomics & Biotechnology ETF position peaked at $17.3M in Q2 2021.
  • 48 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.